Schedule 13G ownership disclosure
THERAVANCE BIOPHARMA INC
Security class unavailable · CUSIP: G8807B106
Event date: 2021-09-30
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 250,219
- Percent of class
- 0.3400%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902219-21-000394
- Form type
- SC 13G
- Filer
- Theravance Biopharma, Inc.
- CIK
- CIK 1583107
- Filed
- Oct 08, 2021
- Reporting period
- Sep 30, 2021
- Description
- Schedule 13G beneficial ownership